LSTA — Lisata Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology
$1.50
-$0.07 (-4.46%)
Lisata Therapeutics Inc. (LSTA) is a biotechnology company listed on NASDAQ. It is led by David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D., based in 110 Allen Road, Basking Ridge, NJ, United States, 07920, with about 21 employees. Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Latest reported LSTA revenue for 2025-09-30 was $0. Net income was -$4.2M. Revenue was down 100.0% from 2025-06-30 to 2025-09-30. LSTA currently screens at market cap $31.7M.
Use this LSTA page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the LSTA quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the LSTA SEC filings page. Lician reads the product cache first so this HTML stays unique to Lisata Therapeutics Inc. even when a live quote feed is slow.
About Lisata Therapeutics Inc.
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
LSTA Key Statistics
Market Cap
$31.69M
Volume
183,900
Previous Close
$1.76
Day Range
$1.72 – $1.89
EPS
-$2.40
Revenue
$1.00M
Net Income
-$19.98M
Gross Profit
$0.00
Free Cash Flow
$0.00
Profit Margin
-1998.5%
Employees
21
LSTA Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $1.00M | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$19.98M | -$20.84M | -$54.23M | -$27.47M |
| EPS (Diluted) | -$2.40 | -$2.58 | -$10.47 | -$7.45 |
Operating Cash Flow
-$19.36M
Free Cash Flow
$0.00
Lisata Therapeutics Inc. Company Information
- President, CEO & Director
- David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D.
- Headquarters
- 110 Allen Road, Basking Ridge, NJ, United States, 07920
- Website
- www.lisata.com
- Phone
- 908 842 0100
- IPO / Founded
- 1999-03-01
- Sector
- Healthcare
- Industry
- Biotechnology